TY - JOUR
T1 - In vitro susceptibility to 19 agents other than β-lactams among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission
AU - On behalf of the DZIF-ATHOS Study Group
AU - Mischnik, A.
AU - Baumert, P.
AU - Hamprecht, A.
AU - Rohde, A. M.
AU - Peter, S.
AU - Feihl, S.
AU - Knobloch, J.
AU - Gölz, H.
AU - Kola, A.
AU - Obermann, B.
AU - Querbach, C.
AU - Willmann, M.
AU - Gebhardt, F.
AU - Tacconelli, E.
AU - Gastmeier, P.
AU - Seifert, H.
AU - Kern, W. V.
AU - Armean, Sabina
AU - Boldt, Anne C.
AU - Bui, Minh Trang
AU - Busch, Dirk
AU - Först, Gesche
AU - Foschi, Federico
AU - Häcker, Georg
AU - Heim, Markus
AU - Hug, Martin
AU - Ihle, Vera
AU - Kaier, Klaus
AU - Kipnis, Marina
AU - Fabian Küpper, M.
AU - Lipp, Hans Peter
AU - Märtin, Nayana
AU - Nordmann, Mathias
AU - Penadiaz, Luis Alberto
AU - Peyerl-Hoffmann, Gabriele
AU - Rupp, Jan
AU - Schneider, Christian
AU - Schröder, Christine
AU - Spohn, Katrin
AU - Steib-Bauert, Michaela
AU - Temme, Sigrun
AU - Vehreschild, Maria
AU - vor dem Esche, Ulrich
AU - Wille, Thorsten
N1 - Publisher Copyright:
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2017
Y1 - 2017
N2 - Objectives: As part of the multicentre Antibiotic Therapy Optimisation Study, MIC values of 19 non-β-lactam agents were determined for third-generation cephalosporin-resistant Escherichia coli, Klebsiella species and Enterobacter species (3GCREB) isolates collected in German hospitals. Methods: A total of 328 E. coli, 35 Klebsiella spp. (1 Klebsiella oxytoca and 34 Klebsiella pneumoniae) and 16 Enterobacter spp. (1 Enterobacter aerogenes and 15 Enterobacter cloacae) isolates were submitted to broth microdilution antimicrobial susceptibility testing with the MICRONAUT system. MICs of fluoroquinolones (levofloxacin and moxifloxacin), aminoglycosides (gentamicin, tobramycin, amikacin, streptomycin, neomycin and paromomycin), tetracyclines (tetracycline, minocycline and tigecycline), macrolides (erythromycin, clarithromycin and azithromycin) and miscellaneous agents [trimethoprim/sulfamethoxazole, chloramphenicol, nitrofurantoin, colistin and fosfomycin intravenous (iv)] were determined and reviewed against 2016 EUCAST breakpoints. Results: The MIC of levofloxacin was>2 mg/L for 128 of 328 E. coli and 8 of 35 Klebsiella spp., but only 1 of 16 Enterobacter spp. Rates of resistance to trimethoprim/sulfamethoxazole were high (>70%), except for Enterobacter spp. Rates of resistance to colistin and fosfomycin iv were still low. About 20% of the tested isolates were resistant to chloramphenicol. Only 1 (of 328) E. coli isolate had an MIC of amikacin >16 mg/L and only 33 of 328 E. coli and 1 of 35 Klebsiella spp. had an MIC of tobramycin >4 mg/L, whereas average gentamicin MICs were in general more elevated. A tigecycline MIC >2 mg/L was only found for 1 of 16 Enterobacter spp., but in none of the E. coli or Klebsiella spp. isolates. Conclusions: Our study gives insight into previously unreported non-β-lactam MIC distributions of 3GCREB isolates.
AB - Objectives: As part of the multicentre Antibiotic Therapy Optimisation Study, MIC values of 19 non-β-lactam agents were determined for third-generation cephalosporin-resistant Escherichia coli, Klebsiella species and Enterobacter species (3GCREB) isolates collected in German hospitals. Methods: A total of 328 E. coli, 35 Klebsiella spp. (1 Klebsiella oxytoca and 34 Klebsiella pneumoniae) and 16 Enterobacter spp. (1 Enterobacter aerogenes and 15 Enterobacter cloacae) isolates were submitted to broth microdilution antimicrobial susceptibility testing with the MICRONAUT system. MICs of fluoroquinolones (levofloxacin and moxifloxacin), aminoglycosides (gentamicin, tobramycin, amikacin, streptomycin, neomycin and paromomycin), tetracyclines (tetracycline, minocycline and tigecycline), macrolides (erythromycin, clarithromycin and azithromycin) and miscellaneous agents [trimethoprim/sulfamethoxazole, chloramphenicol, nitrofurantoin, colistin and fosfomycin intravenous (iv)] were determined and reviewed against 2016 EUCAST breakpoints. Results: The MIC of levofloxacin was>2 mg/L for 128 of 328 E. coli and 8 of 35 Klebsiella spp., but only 1 of 16 Enterobacter spp. Rates of resistance to trimethoprim/sulfamethoxazole were high (>70%), except for Enterobacter spp. Rates of resistance to colistin and fosfomycin iv were still low. About 20% of the tested isolates were resistant to chloramphenicol. Only 1 (of 328) E. coli isolate had an MIC of amikacin >16 mg/L and only 33 of 328 E. coli and 1 of 35 Klebsiella spp. had an MIC of tobramycin >4 mg/L, whereas average gentamicin MICs were in general more elevated. A tigecycline MIC >2 mg/L was only found for 1 of 16 Enterobacter spp., but in none of the E. coli or Klebsiella spp. isolates. Conclusions: Our study gives insight into previously unreported non-β-lactam MIC distributions of 3GCREB isolates.
UR - http://www.scopus.com/inward/record.url?scp=85020090929&partnerID=8YFLogxK
U2 - 10.1093/jac/dkw577
DO - 10.1093/jac/dkw577
M3 - Journal articles
C2 - 28108677
AN - SCOPUS:85020090929
SN - 0305-7453
VL - 72
SP - 1359
EP - 1363
JO - Journal of Antimicrobial Chemotherapy
JF - Journal of Antimicrobial Chemotherapy
IS - 5
ER -